Bioactive Components from Ginger, Tea and Apple Prevent Protein Glycation by Trapping Methylglyoxal with Potential in Alleviation of Diabetic Complications by Sang, Shengmin

Get full text
Get full text

Image_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

DataSheet_1_Dysregulation of iron metabolism modulators in virologically suppressed HIV-infected patients.docx by Vanesa Garrido-Rodríguez (14172573)

“…Since virologically suppressed chronic HIV-infected subjects under effective antiretroviral treatment (ART) exhibit a persistent immune dysfunction that leads to comorbidities, iron homeostasis may be relevant in this context. …”

datasheet1_Spatio-Temporal Variability of Peat CH4 and N2O Fluxes and Their Contribution to Peat GHG Budgets in Indonesian Forests and Oil Palm Plantations.docx by Erin Swails (10323518)

“…The objective of our research was to assess changes in peat GHG flux and budget associated with peat swamp forest disturbance and conversion to oil palm plantation and to evaluate drivers of variation in trace gas fluxes. Over a period of one and a half year, we monitored monthly CH₄ and N₂O fluxes together with environmental variables in three undrained peat swamp forests and three oil palm plantations on peat in Central Kalimantan. …”

Data_Sheet_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.docx by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Northern blot analysis of riRNA. by Hiraku Takada (3599702)

“…The level of rRNA markedly decreased in the stationary phase. [C] <i>E</i>. <i>coli</i> BW25113 was grown in M9-glucose medium, and in the middle of exponential phase, total RNA was prepared using Isogen and subjected to Northern blot analysis using a series of Northern probes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>, probes N01 to N10). riRNA was detected using two specific probes, probe-N3 and probe-N4 (for probes see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>; and for primers used for amplification of these probes, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.s005" target="_blank">S2 Table</a>). …”

Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

“…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”

Pharmacoeconomic Evaluations of Oral Anticancer Agents. Thematic Systematic Review by Alkadour, Ahmad Amer

Get full text
Get full text

<strong>Bull trout streamflow and temperature linear SCR model</strong> by Patti Wohner (16398345)

“…These extremes provided a unique opportunity to retrospectively compare bull trout survival and migration under potential climate change scenarios. …”

Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

“…Yellow: increased, dark grey: decreased, light grey: unchanged. (M) Bar plots show the percentage of glomeruli exhibiting a change in response for cued vs. un-cued trials. …”

Phenotypic characterization of <i>CsIVP</i>-RNAi transgenic plants. by Shuangshuang Yan (798064)

“…Scale bars represent 2 cm in panels A, D–J, and P; 2 mm in panel K; 200 μm in panels L–O; 50 μm in panels L’–O’; and 100 μm in panels R–U. …”

P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab). by Hong Yan Huang (20135965)

“…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”

Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”